Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Csaki Huttner, Angela
Siegrist, Claire-Anne

Publication date

January 2018

DOI

10.1080/14760584.2018.1546582

Publisher

Informa UK Limited

ISSN

1476-0584

Citation count (estimate)

1

Abstract

The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown

Extracted data

Related items

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Hoff, Nicole A
Bratcher, Anna
Kelly, J Daniel
Musene, Kamy
Kompany, Jean Paul
Kabamba, Michel
Mbala-Kingebeni, Placide
Dighero-Kemp, Bonnie
Kocher, Gregory
Elliott, Elizabeth
Reilly, Cavan
Halbrook, Megan
Kebela, Benoit Ilunga
Gadoth, Adva
Mwamba, Guillaume Ngoie
Tambu, Merly
McIlwain, David R
Mukadi, Patrick
Hensley, Lisa E
Ahuka-Mundeke, Steve
Rutherford, George W
Muyembe-Tamfum, Jean Jacques
Rimoin, Anne W

February 2022

Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered duri...

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Henao-Restrepo, Ana Maria
Longini, Ira M
Egger, Matthias
Dean, Natalie E
Edmunds, W John
Camacho, Anton
Carroll, Miles W
Doumbia, Moussa
Draguez, Bertrand
Duraffour, Sophie
Enwere, Godwin
Grais, Rebecca
Gunther, Stephan
Hossmann, Stefanie
Kondé, Mandy Kader
Kone, Souleymane
Kuisma, Eeva
Levine, Myron M
Mandal, Sema
Norheim, Gunnstein
Riveros, Ximena
Soumah, Aboubacar
Trelle, Sven
Vicari, Andrea S
Watson, Conall H
Kéïta, Sakoba
Kieny, Marie Paule
Røttingen, John-Arne

August 2015

BACKGROUND: A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing...

Investigating the Antibody Immune Response to Ebola Virus Vaccination in Humans

Ehrhardt, Stefanie A.

January 2022

As the most advanced Ebola virus vaccine candidate, recombinant vesicular stomatitis virus–Zaire Ebo...

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Csaki Huttner, Angela
Agnandji, Selidji Todagbe
Combescure, Christophe
Fernandes, José F
Bache, Emmanuel Bache
Kabwende, Lumeka
Ndungu, Francis Maina
Brosnahan, Jessica
Monath, Thomas P
Lemaitre, Barbara
Grillet, Stéphane
Botto, Miriam
Engler, Olivier
Portmann, Jasmine
Siegrist, Denise
Bejon, Philip
Silvera, Peter
Kremsner, Peter
Siegrist, Claire-Anne

January 2018

The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) g...

Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates

Chad E. Mire (328797)
Joan B. Geisbert (328802)
Krystle N. Agans (499740)
Benjamin A. Satterfield (554677)
Krista M. Versteeg (554678)
Elizabeth A. Fritz (554679)
Heinz Feldmann (18301)
Lisa E. Hensley (202167)
Thomas W. Geisbert (328805)

April 2014

<div><p>The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with ...

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Chad E Mire
Joan B Geisbert
Krystle N Agans
Benjamin A Satterfield
Krista M Versteeg
Elizabeth A Fritz
Heinz Feldmann
Lisa E Hensley
Thomas W Geisbert

The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mor...

Efficacy and Effectiveness of an rVSV-Vectored Vaccine Expressing Ebola Surface Glycoprotein: Interim Results from the Guinea Ring Vaccination Cluster-Randomised Trial

Henao-Restrepo, A M
Longini, I M
Egger, M
Dean, N E
Edmunds, W J
Camacho, A
Carroll, M W
Doumbia, M
Draguez, B
Duraffour, S
Enwere, G
Grais, R
Gunther, S
Hossmann, S
Kondé, M K
Kone, S
Kuisma, E
Levine, M M
Mandal, S
Norheim, G
Riveros, X
Soumah, A
Trelle, S
Vicari, A S
Watson, C H
Kéïta, S
Kieny, M P
Røttingen, J-A

August 2015

A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface g...

Correlates of vaccine-induced protective immunity against Ebola virus disease

Medaglini, Donata
Santoro, Francesco
Siegrist, Claire-Anne

January 2018

Ebola virus disease is a deadly infection which occurs in sporadic outbreaks. Several vaccine candid...

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

January 2016

Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine exp...

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report

January 2016

The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Z...

Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)

December 2016

rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccin...

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of

Ebola Virus
John H. Eldridge
Heinz Feldmann
David K. Clarke

September 2016

Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycopro...

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.

Courtney Woolsey
Robert W Cross
Krystle N Agans
Viktoriya Borisevich
Daniel J Deer
Joan B Geisbert
Cheryl Gerardi
Theresa E Latham
Karla A Fenton
Michael A Egan
John H Eldridge
Thomas W Geisbert
Demetrius Matassov

May 2022

BackgroundMarburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as d...

Persistence of immune responses induced by Ebola virus vaccines.

Snape, M

January 2017

The recent devastating outbreak of Ebola virus disease led to the accelerated development of multipl...

Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates

Geisbert, Thomas W.
Daddario-DiCaprio, Kathleen M.
Lewis, Mark G.
Geisbert, Joan B.
Grolla, Allen
Leung, Anders
Paragas, Jason
Matthias, Lennox
Smith, Mark A.
Jones, Steven M.
Hensley, Lisa E.
Feldmann, Heinz
Jahrling, Peter B.

November 2008

Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as an emerg...

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Hoff, Nicole A
Bratcher, Anna
Kelly, J Daniel
Musene, Kamy
Kompany, Jean Paul
Kabamba, Michel
Mbala-Kingebeni, Placide
Dighero-Kemp, Bonnie
Kocher, Gregory
Elliott, Elizabeth
Reilly, Cavan
Halbrook, Megan
Kebela, Benoit Ilunga
Gadoth, Adva
Mwamba, Guillaume Ngoie
Tambu, Merly
McIlwain, David R
Mukadi, Patrick
Hensley, Lisa E
Ahuka-Mundeke, Steve
Rutherford, George W
Muyembe-Tamfum, Jean Jacques
Rimoin, Anne W

February 2022

Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered duri...

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Henao-Restrepo, Ana Maria
Longini, Ira M
Egger, Matthias
Dean, Natalie E
Edmunds, W John
Camacho, Anton
Carroll, Miles W
Doumbia, Moussa
Draguez, Bertrand
Duraffour, Sophie
Enwere, Godwin
Grais, Rebecca
Gunther, Stephan
Hossmann, Stefanie
Kondé, Mandy Kader
Kone, Souleymane
Kuisma, Eeva
Levine, Myron M
Mandal, Sema
Norheim, Gunnstein
Riveros, Ximena
Soumah, Aboubacar
Trelle, Sven
Vicari, Andrea S
Watson, Conall H
Kéïta, Sakoba
Kieny, Marie Paule
Røttingen, John-Arne

August 2015

BACKGROUND: A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing...

Investigating the Antibody Immune Response to Ebola Virus Vaccination in Humans

Ehrhardt, Stefanie A.

January 2022

As the most advanced Ebola virus vaccine candidate, recombinant vesicular stomatitis virus–Zaire Ebo...

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Csaki Huttner, Angela
Agnandji, Selidji Todagbe
Combescure, Christophe
Fernandes, José F
Bache, Emmanuel Bache
Kabwende, Lumeka
Ndungu, Francis Maina
Brosnahan, Jessica
Monath, Thomas P
Lemaitre, Barbara
Grillet, Stéphane
Botto, Miriam
Engler, Olivier
Portmann, Jasmine
Siegrist, Denise
Bejon, Philip
Silvera, Peter
Kremsner, Peter
Siegrist, Claire-Anne

January 2018

The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) g...

Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates

Chad E. Mire (328797)
Joan B. Geisbert (328802)
Krystle N. Agans (499740)
Benjamin A. Satterfield (554677)
Krista M. Versteeg (554678)
Elizabeth A. Fritz (554679)
Heinz Feldmann (18301)
Lisa E. Hensley (202167)
Thomas W. Geisbert (328805)

April 2014

<div><p>The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with ...

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Chad E Mire
Joan B Geisbert
Krystle N Agans
Benjamin A Satterfield
Krista M Versteeg
Elizabeth A Fritz
Heinz Feldmann
Lisa E Hensley
Thomas W Geisbert

The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mor...

Efficacy and Effectiveness of an rVSV-Vectored Vaccine Expressing Ebola Surface Glycoprotein: Interim Results from the Guinea Ring Vaccination Cluster-Randomised Trial

Henao-Restrepo, A M
Longini, I M
Egger, M
Dean, N E
Edmunds, W J
Camacho, A
Carroll, M W
Doumbia, M
Draguez, B
Duraffour, S
Enwere, G
Grais, R
Gunther, S
Hossmann, S
Kondé, M K
Kone, S
Kuisma, E
Levine, M M
Mandal, S
Norheim, G
Riveros, X
Soumah, A
Trelle, S
Vicari, A S
Watson, C H
Kéïta, S
Kieny, M P
Røttingen, J-A

August 2015

A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface g...

Correlates of vaccine-induced protective immunity against Ebola virus disease

Medaglini, Donata
Santoro, Francesco
Siegrist, Claire-Anne

January 2018

Ebola virus disease is a deadly infection which occurs in sporadic outbreaks. Several vaccine candid...

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

January 2016

Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine exp...

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report

January 2016

The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Z...

Efficacy and Effectiveness of an rVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)

December 2016

rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccin...

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of

Ebola Virus
John H. Eldridge
Heinz Feldmann
David K. Clarke

September 2016

Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycopro...

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.

Courtney Woolsey
Robert W Cross
Krystle N Agans
Viktoriya Borisevich
Daniel J Deer
Joan B Geisbert
Cheryl Gerardi
Theresa E Latham
Karla A Fenton
Michael A Egan
John H Eldridge
Thomas W Geisbert
Demetrius Matassov

May 2022

BackgroundMarburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as d...

Persistence of immune responses induced by Ebola virus vaccines.

Snape, M

January 2017

The recent devastating outbreak of Ebola virus disease led to the accelerated development of multipl...

Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates

Geisbert, Thomas W.
Daddario-DiCaprio, Kathleen M.
Lewis, Mark G.
Geisbert, Joan B.
Grolla, Allen
Leung, Anders
Paragas, Jason
Matthias, Lennox
Smith, Mark A.
Jones, Steven M.
Hensley, Lisa E.
Feldmann, Heinz
Jahrling, Peter B.

November 2008

Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as an emerg...

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Hoff, Nicole A
Bratcher, Anna
Kelly, J Daniel
Musene, Kamy
Kompany, Jean Paul
Kabamba, Michel
Mbala-Kingebeni, Placide
Dighero-Kemp, Bonnie
Kocher, Gregory
Elliott, Elizabeth
Reilly, Cavan
Halbrook, Megan
Kebela, Benoit Ilunga
Gadoth, Adva
Mwamba, Guillaume Ngoie
Tambu, Merly
McIlwain, David R
Mukadi, Patrick
Hensley, Lisa E
Ahuka-Mundeke, Steve
Rutherford, George W
Muyembe-Tamfum, Jean Jacques
Rimoin, Anne W

February 2022

Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered duri...

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Henao-Restrepo, Ana Maria
Longini, Ira M
Egger, Matthias
Dean, Natalie E
Edmunds, W John
Camacho, Anton
Carroll, Miles W
Doumbia, Moussa
Draguez, Bertrand
Duraffour, Sophie
Enwere, Godwin
Grais, Rebecca
Gunther, Stephan
Hossmann, Stefanie
Kondé, Mandy Kader
Kone, Souleymane
Kuisma, Eeva
Levine, Myron M
Mandal, Sema
Norheim, Gunnstein
Riveros, Ximena
Soumah, Aboubacar
Trelle, Sven
Vicari, Andrea S
Watson, Conall H
Kéïta, Sakoba
Kieny, Marie Paule
Røttingen, John-Arne

August 2015

BACKGROUND: A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing...

Investigating the Antibody Immune Response to Ebola Virus Vaccination in Humans

Ehrhardt, Stefanie A.

January 2022

As the most advanced Ebola virus vaccine candidate, recombinant vesicular stomatitis virus–Zaire Ebo...